

October 17, 2016



Heat Biologics to Present at Two Upcoming Investor Conferences and Panel Discussion

DURHAM, N.C., Oct. 17, 2016 (GLOBE NEWSWIRE) -- [Heat Biologics, Inc.](#) ("Heat") (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that Jeff Wolf, CEO of Heat is scheduled to present at the following investor conferences:

BIO Investor Forum

Date: Tuesday, October 18, 2016

Time: 3:30 PM Eastern Time

Location: Westin St. Francis Hotel in San Francisco, CA

Main Therapeutic Focus: Immunology

Webcast: <http://ir.heatbio.com/events-presentations>. The webcast will be archived on the company's website for a period of three months.

The Dawson James Growth Stock Conference

Date: Thursday, October 20, 2016

Time: 10:00 AM Eastern Time

Location: Wyndham Grand Hotel in Jupiter, FL

Webcast: <http://ir.heatbio.com/events-presentations>. The webcast will be archived on the company's website for a period of three months.

Additionally, Chief Scientific Officer, Taylor Schreiber, M.D., Ph.D., will participate in a panel discussion on "The Sizzling Science and Business of Immuno-Oncology" at the North Carolina Biotechnology Center, on October 25th, from 4-7 PM. For more information on the panel please go to: <http://www.ncbiotech.org/event/life-sciences-forum/191426>.

About Heat Biologics, Inc.

Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer. Heat's highly specific T cell-stimulating platform technologies, *ImPACT* and *ComPACT*, form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ "killer" T cells (one of the human immune system's most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients' immune response. Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumacel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer.

(NSCLC). For more information, please visit www.heatbio.com.

CONTACT:

For Investor Inquiries:

David Waldman

919-240-7133

Investorrelations@heatbio.com

For Media Inquiries:

Deanne Eagle

Planet Communications

917-837-5866

deanne@planetcommunications.nyc



Source: Heat Biologics